Compare Supplements

Prescription dosing is 75 mg or 150 mg subcutaneously every 2 weeks (a 300 mg every-4-weeks option exists), titrated by a clinician to the LDL-C target. A prescription drug; not a self-administered supplement regimen.

Any time

Subcutaneous prefilled pen/syringe (alirocumab)

284 mg (300 mg inclisiran sodium) by subcutaneous injection administered by a healthcare professional on day 1, again at day 90 (month 3), then every 6 months thereafter. A prescription drug; this is the approved regimen, not a self-directed supplement protocol.

Any time

Prefilled subcutaneous injection (inclisiran 284 mg)

• Known serious hypersensitivity to alirocumab or excipients
• Pregnancy (limited data; lipid lowering generally deferred in pregnancy)

• Statins
• Other lipid-lowering agents (ezetimibe)

• Known hypersensitivity to inclisiran or excipients
• Not a substitute for a clinician's evaluation — prescription drug only

• Statins / ezetimibe
• PCSK9 monoclonal antibodies (evolocumab / alirocumab)